Non-natural Fuc analog-based cell surface MOE is based on the principle of modifying cellular interactions with other cells or molecules by introducing non-natural Fuc analogs that modulate the structure of the glycan groups on the cell surface. This opens up the possibility of designing and optimizing targeted immunotherapies. For example, enhancement of anti-tumor immune responses by enhancing the interaction between immune cells and tumor cells. This technology can also be used in the discovery and development of innovative drugs. While many current drugs are designed based on the principle that specific molecules interact with cell surface glycan structures, the introduction of non-natural Fuc analogs can precisely modulate cell surface glycan structures, thereby altering the target or mode of action of the drug and improving drug efficacy and specificity.
Fig.1 Strategies of MOE. (Campbell, et al., 2007)
CD BioGlyco provides non-natural Fuc analog-based Cell Surface MOE Services with superior technology and a specialized Glycoengineering Platform. We use non-natural Fuc analogs to modification of glycosylation on the cell surface to achieve precise modulation of specific protein-glycan interactions. Below are details about our services:
Fig.2 Applications of non-natural Fuc analog-based cell surface MOE. (CD BioGlyco)
CD BioGlyco offers non-natural Fuc analogs-based cell surface MOE services to help clients achieve precise Cell Surface Glycoengineering for various research and application needs. We aim to provide valuable assistance to researchers and scientists in their studies on glycobiology. Please feel free to contact us if you have any questions regarding our services.
Reference
About Us
CD BioGlyco is a leading biotechnology company specializing in glycobiology. We deliver high-quality products and services to support cutting-edge research worldwide.